Elon Musk's absurd Tesla pay packet to stop him from leaving
The deal, announced in an SEC filing, grants Musk 96 million new shares in Tesla, which has been in a prolonged sales slump that has hurt the company's stock performance this year.
Shares were up two per cent in mid-day trading.
'While we recognise Elon's business ventures, interests and other potential demands on his time and attention are extensive and wide-ranging … we are confident that this award will incentivise Elon to remain at Tesla,' members of a special committee formed to consider Musk's pay said in the filing.
Last year, a Delaware judge nixed Musk's original stock-based compensation package, which was worth more than $A77.2 billion, after finding it was too excessive and unfair to shareholders.
Musk was so incensed by the decision that he moved Tesla's state of incorporation from Delaware to Texas.
Musk, who is already the world's richest person with a real-time net worth of $A614.7 billion according to Bloomberg, filed an appeal in March challenging the Delaware judge's ruling.
Tesla's special committee said there would be no 'double dip' if the original deal is eventually restored.
Instead, the $A44.7 billion package will either be voided or offset.
The special committee consists of just two members – Tesla chair Robyn Denholm and board director Kathleen Wilson-Thompson.
Musk is already Tesla's largest individual shareholder and owns roughly 13 per cent of the company.
The announcement removed a key 'overhang' on Tesla's shares and should help calm investors with questions about Musk's commitment, according to Wedbush analyst Dan Ives.
'Musk remains Tesla's big asset and this comp issue has been a constant concern of shareholders once the Delaware soap opera began,' Ives wrote in a note to clients.
Ives added that it is critical for Tesla's board to 'get this long-term compensation strategy in place prior to the company's November 6th shareholder meeting which would address the elephant in the room.'
According to the deal's terms, Musk's new shares will only vest if he remains a key executive at Tesla through at least 2027.
The shares also come with a five-year lockup, with Musk only able to sell to cover tax payments.
Critics have long alleged that Musk is overpaid compared to other Big Tech CEOs, such as Microsoft's Satya Nadella and Google's Sundar Pichai, who have led their companies to share price growth without monster pay packages.
Just a few executives have secured deals worth $1.5 billion or more annually in recent years, according to the Wall Street Journal.
That includes Palantir boss Alexander Karp, who earned more than $A9.2 billion last year, and Hock Tan of chip maker Broadcom, who earned $A1.7 billion.
Musk will need to redouble efforts to lead a turnaround at Tesla. Analysts have pointed to Tesla's ageing car line-up and increased competition from Chinese automakers like BYD as key obstacles for the company.
Musk's political adventures, including his work with the Department of Government Efficiency and public clashes with President Trump, have also worried stockholders.
The Tesla CEO has cited AI initiatives, such as Tesla's self-driving Robotaxis and Optimus humanoid robots, as central to its long-term business strategy.
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
News.com.au
11 minutes ago
- News.com.au
NFL buys 10% stake in ESPN, which buys NFL Network, RedZone
The NFL sold its NFL Network and Sunday RedZone television show to ESPN on Tuesday in exchange for a 10% equity stake in the US-based sports television network. Both companies announced the deal, which also includes the combining of NFL Fantasy Football with ESPN Fantasy Football. Federal regulators must approve the transaction, a process that could take several months, according to the league. Until the deal closes, fans are unlikely to see any significant changes to ESPN or NFL Network. NFL team owners also must approve the deal, but that is seen as little more than a formality given the expanded reach on offer for NFL programming. "I think we've hooked up with the best partners we can have," said New England Patriots owner Robert Kraft, chairman of the NFL's media committee. "That will help expose us to more homes, more of an international audience. Strategically, we have to grow our salary cap and can only do that by -- if we want to keep labor peace, we have to grow our audience. This transaction helps us to do that." Global growth opportunities for the NFL, which already plays games overseas every season, played a key role in motivating the NFL to get terms of the deal sorted. "We're hooking up with the strongest sports amalgamation of sports product," Kraft said. "We're giving them what I believe is the best content, and they're giving us the greatest operational company to grow our audience globally. "This is a way for us to broaden our audience. We've done so much. I don't think there's any company like (ESPN owners) Disney and ESPN in doing sports, all sports. We need to expose our product to more people and a greater variety of people."
The Australian
an hour ago
- The Australian
Trump says pharma, chips tariffs incoming as trade war widens
US President Donald Trump signaled Tuesday that fresh tariffs on imported pharmaceuticals and semiconductors could be unveiled within the coming week, as a cascade of incoming duties promises to reshape global trading ties. Governments around the world are bracing as new waves of US tariffs are due to take effect this week, first on many Brazilian products Wednesday and then on dozens of other economies -- including the European Union and Taiwan -- beginning Thursday. Trump's sweeping plans have sparked a flurry of activity as leaders seek to avert the worst of his threats, with Swiss officials heading to Washington on Tuesday in a last-minute push to avoid punitive duties. But the US president appears set to widen his trade wars. Trump told CNBC on Tuesday that upcoming tariffs on imported pharmaceuticals could reach 250 percent, while adding that he plans for new duties on foreign semiconductors soon. "We'll be putting (an) initially small tariff on pharmaceuticals, but in one year, one-and-a-half years, maximum, it's going to go to 150 percent," Trump said. "And then it's going to go to 250 percent because we want pharmaceuticals made in our country." Trump also said that Washington will be announcing tariffs "within the next week or so." He added: "We're going to be announcing on semiconductors and chips." - India threat - Trump has set out varying tariff rates for dozens of economies after imposing a 10-percent levy on almost all trading partners in April. But these broad duties taking effect Thursday exclude products like pharmaceuticals, steel, aluminum and lumber, which are being separately targeted by sector. This means that although the 39-percent tariff Swiss leaders seek to avoid come Thursday excludes pharmaceuticals, Trump's plans for a steep levy on such imports will likely remain a point of contention in any talks. Pharmaceuticals represented 60 percent of Swiss goods exports to the United States last year. Outside of Switzerland, most products from the European Union face a 15 percent tariff starting Thursday, after Washington and Brussels struck a deal to avoid higher levies. But Trump warned Tuesday that the EU could see its tariff level surge again if it did not fulfill obligations under their recent pact. Some imports from Canada are also targeted by tariffs, although Prime Minister Mark Carney stressed Tuesday that more than 85 percent of trade between the North American neighbors remains tariff-free under existing exemptions. Besides probing pharmaceuticals and chips imports, Trump has already imposed steep duties of 50 percent on steel and aluminum, alongside lower levies on autos and parts. In the same CNBC interview Tuesday, Trump said he expects to raise the US tariff on Indian imports "very substantially over the next 24 hours" due to the country's purchases of Russian oil. This is a key revenue source for Moscow's military offensive on Ukraine. His pressure on India comes after signaling fresh sanctions on Moscow if it did not make progress by Friday towards a peace deal with Kyiv, more than three years since Russia's invasion. Moscow is anticipating talks this week with the US leader's special envoy Steve Witkoff, and the Kremlin has criticized Trump's threat of raising tariffs on Indian goods. Weak employment data last week pointed to challenges for the US economy as companies take a cautious approach in hiring and investment while grappling with Trump's radical -- and rapidly changing -- trade policy. The tariffs are a demonstration of raw economic power that Trump sees as putting US exporters in a stronger position while encouraging domestic manufacturing by keeping out foreign imports. But the approach has raised fears of inflation and other economic fallout in the world's biggest economy. bys/jgc
The Australian
an hour ago
- The Australian
Donald Trump threatens pharmaceutical tariffs of 250 per cent
Donald Trump has threatened to slap tariffs of up to 250 per cent on foreign-made pharmaceuticals – a move that would hit Australian producers hard. The US President last month flagged his administration was planning imposts of up to 200 per cent on pharmaceuticals, giving drugmakers up to 'a year and a half to come in'. But in an interview overnight, he said he wanted to tighten the timeline. 'We'll be putting (an) initially small tariff on pharmaceuticals,' Mr Trump told US business news channel CNBC. 'In one year, 1½ years maximum, it's going to go to 150 per cent and then it's going to go to 250 per cent because½ we want pharmaceuticals made in our country.' He did not say what the initial rate would be, but earlier in the year he said duties on the sector would start from 25 per cent. Mr Trump caused a stir in Canberra when he first announced he was mulling over tariffs on pharmaceuticals, with Treasurer Jim Chalmers saying the Albanese government was 'urgently seeking' details. Australian pharma exports to the US were worth more than $2bn in 2024. Exports are mostly blood products and vaccines but also include packaged medicines and miscellaneous products, such as bandages. But Mr Trump's threat to hit the industry with steep levies is driven by ire over high prices in the US rather than animosity towards allies. A RAND Corporation report found that Americans pay nearly four times than Australians for medicines and about three times more than the average in other developed economies. In Australia, that is largely due to the Pharmaceutical Benefits Scheme, which compels drugmakers to negotiate prices with the federal government if they want to sell their products. Similar mechanisms exist in New Zealand, Canada, the UK and Europe. Mr Trump last week wrote to 17 major pharmaceutical firms demanding they lower their prices for American consumers and bring them in line with prices overseas. Read related topics: Donald Trump Breaking News Controversial MP Mark Latham has escaped parliamentary condemnation after he was accused of sharing confidential information. Breaking News The Storm famously sent Harry Grant to the Wests Tigers in a move that helped him develop immensely. Now they could do something similar.
